Supriya LifescienceNSE:SUPRIYA -1.62%75 ROA % is 21.88% as of Mar. 2026, which is 24% above its 10-year median of 17.71. GuruFocus rates NSE:SUPRIYA with a GF Score™ of 75/100 and a GF Value™ of ₹805.46 (Modestly Overvalued). The stock has 8 warning signs investors should review. Among 1,417 Biotechnology companies, Supriya Lifescience ranks better than 95.06% on this metric.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Supriya Lifescience's annualizedNet Income for the quarter that ended in Mar. 2026 was ₹2,969 Mil.
Supriya Lifescience's average Total Assets over the quarter that ended in Mar. 2026 was ₹13,571 Mil. Therefore, Supriya Lifescience's annualized ROA % for the quarter that ended in Mar. 2026 was 21.88%.
The historical rank and industry rank for Supriya Lifescience's ROA % or its related term are showing as below:
NSE:SUPRIYA'
s ROA % Range Over the Past 10 Years
Min: 11.56 Med: 17.71 Max: 31.61
Current: 17.08
During the past 8 years, Supriya Lifescience's highest ROA % was 31.61%. The lowest was 11.56%. And the median was 17.71%.
NSE:SUPRIYA's ROA % is ranked better than 95.06% of 1417
companies
in the Biotechnology industry
Industry Median: -32.84
vs NSE:SUPRIYA: 17.08
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
Supriya Lifescience ROA % Related Terms
Supriya Lifescience ROA % Historical Data
* Premium members only.
The historical data trend for Supriya Lifescience's ROA % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Supriya Lifescience's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Supriya Lifescience ROA % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Supriya Lifescience's ROA % distribution charts can be found below:
* The bar in red indicates where Supriya Lifescience's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
ROA % is displayed in the 30-year financial page.
Supriya Lifescience (NSE:SUPRIYA) has a ROA % of 21.88% as of Mar. 2026. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Supriya Lifescience and its competitors. This is 24% above median its historical median of 17.71. Over the past decade, Supriya Lifescience's ROA % has ranged from 11.56 to 31.61. According to the industry distribution chart, Supriya Lifescience ranks #70 out of 1417 companies in the Biotechnology industry, placing it in the top 4.9%.
Is Supriya Lifescience's ROA % too high?
Supriya Lifescience's current ROA % of 21.88% is 24% above median its 10-year median of 17.71. Over the past 10 years, this metric has ranged from a low of 11.56 to a high of 31.61. Based on the distribution chart, Supriya Lifescience ranks #70 out of 1417 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Supriya Lifescience has a GF Score™ of 75/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Supriya Lifescience's ROA % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Supriya Lifescience ranks #70 out of 1417 companies for ROA %. This places Supriya Lifescience in the top 5% of its industry — outperforming the majority of peers. Historically, Supriya Lifescience's own ROA % has ranged from 11.56 to 31.61 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Biotechnology company?
A good ROA % depends on the Biotechnology industry context. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Supriya Lifescience and its competitors. Supriya Lifescience's current ROA % is 21.88%, which is 24% above median its own 10-year median of 17.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Supriya Lifescience stock overvalued right now?
Based on GuruFocus' analysis, Supriya Lifescience (NSE:SUPRIYA) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹805.46, compared to a current price of ₹978.90 — trading 21.5% above its estimated fair value. The current ROA % is 21.88%, which is 24% above median its 10-year median of 17.71. Supriya Lifescience's overall GF Score™ is 75/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Supriya Lifescience (NSE:SUPRIYA), the current ROA % is 21.88% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Supriya Lifescience (NSE:SUPRIYA) Overvalued in 2026?
Based on GuruFocus' analysis, Supriya Lifescience stock appears to be overvalued.
The current stock price of ₹978.90 is trading 21.5% above its estimated GF Value™ of ₹805.46.
GuruFocus considers Supriya Lifescience to be Modestly Overvalued.
Key valuation signals for NSE:SUPRIYA:
ROA %: 21.88% (24% above median its 10-year median of 17.71)
GF Value™: ₹805.46 vs. price of ₹978.90 (21.5% above fair value)
No single metric tells the full story. See the NSE:SUPRIYA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Supriya Lifescience Ltd is a manufacturer of Active Pharmaceutical Ingredients. It is focused on diverse therapeutic segments such as antihistamines, analgesics, anaesthetics, vitamins, anti-asthmatic, and anti-allergic.
75GF Score
Get the complete analysis for NSE:SUPRIYA
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:SUPRIYA has been successfully added to your 
